Verity & Verity LLC Raises Position in Kenvue Inc. $KVUE

Verity & Verity LLC grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 12.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 48,457 shares of the company’s stock after acquiring an additional 5,319 shares during the period. Verity & Verity LLC’s holdings in Kenvue were worth $1,014,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Kenvue by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after acquiring an additional 10,600,682 shares in the last quarter. Third Point LLC purchased a new position in shares of Kenvue during the first quarter valued at approximately $213,422,000. Maverick Capital Ltd. bought a new stake in shares of Kenvue in the 1st quarter worth approximately $203,036,000. American Century Companies Inc. grew its stake in shares of Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after buying an additional 8,436,166 shares during the last quarter. Finally, Nuveen LLC bought a new position in Kenvue during the 1st quarter valued at approximately $187,123,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $16.92 on Tuesday. The firm has a market capitalization of $32.41 billion, a P/E ratio of 22.53 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The business has a fifty day moving average of $16.14 and a 200 day moving average of $19.72.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.9%. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on KVUE shares. Barclays increased their target price on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. The Goldman Sachs Group decreased their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Zacks Research raised Kenvue to a “strong sell” rating in a report on Monday, August 11th. Finally, JPMorgan Chase & Co. lowered their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.